Literature DB >> 25424158

Intramedullary nailing of femoral diaphyseal metastases: is it necessary to protect the femoral neck?

Bryan Moon1, Patrick Lin, Robert Satcher, Justin Bird, Valerae Lewis.   

Abstract

BACKGROUND: Intramedullary nailing is the accepted form of treatment for impending or pathologic fractures of the femoral diaphysis. Traditional teaching promotes the use of a cephalomedullary nail so that stabilization is provided for the femoral neck in the event that a future femoral neck metastasis develops. However, that approach may add cost, surgical time, blood loss, and added radiation exposure to staff members, and there is limited evidence in the literature that supports this practice. QUESTIONS/PURPOSES: The purpose of our study was to evaluate the incidence of femoral neck metastases in patients who underwent femoral nailing of diaphyseal metastases. PATIENTS AND METHODS: Retrospective analysis of our Musculoskeletal Oncology database identified 145 femoral nailings performed for metastatic disease, myeloma, or lymphoma of the femoral diaphysis between 2001 and 2011. Average patient age was 59 years. One hundred forty-one patients underwent 145 femoral nailings (four were bilateral). One hundred forty-four of the nails used were cephalomedullary implants and one was a flexible nail. Thirty-six (25%) femurs had sustained a pathologic fracture and 109 (75%) femurs were treated as impending fractures. Eighty-four patients received either preoperative or postoperative radiation therapy. Average radiographic followup was 13 months and average postoperative survival was 16 months. Of the 141 patients in this series, 121 (86%) are known to have died at a median of 9 months (range, 0.1-133 months) after surgery. The latest followup radiographs were obtained at a median of 5 months after the femoral nailing (range, 0-119 months). Of the 90 patients with documented dates of death and radiographic followup greater than zero months, 76 (84%) had radiographs available within a year of death. Thirty-one patients had zero months radiographic followup. The median survival for this group of patients was only 0.9 months (range, 0.1-12 months).
RESULTS: No patients (0%) in this series had femoral neck metastases develop postoperatively.
CONCLUSION: Despite traditional teaching that supports the use of cephalomedullary implants when treating metastatic disease of the femur, we were unable to identify a single patient who had femoral neck metastasis after surgery on the femur. Our findings do not support the use of cephalomedullary implants in this patient population for the sole purpose of prophylactic femoral neck stabilization; however, this series was relatively small, and the experiences of other centers will be needed to come to a more-complete sense of the frequency of what in all likelihood is a rare event.

Entities:  

Mesh:

Year:  2014        PMID: 25424158      PMCID: PMC4353549          DOI: 10.1007/s11999-014-4064-1

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  18 in total

Review 1.  Controversies in the surgical management of skeletal metastases.

Authors:  H C F Bauer
Journal:  J Bone Joint Surg Br       Date:  2005-05

2.  Management of lower-extremity bone metastasis.

Authors:  Kristy L Weber; R Lor Randall; Seth Grossman; Javad Parvizi
Journal:  J Bone Joint Surg Am       Date:  2006-12       Impact factor: 5.284

Review 3.  Metastatic bone disease: diagnosis, evaluation, and treatment.

Authors:  J Sybil Biermann; Ginger E Holt; Valerae O Lewis; Herbert S Schwartz; Michael J Yaszemski
Journal:  J Bone Joint Surg Am       Date:  2009-06       Impact factor: 5.284

4.  Benefits of early intramedullary nailing in femoral metastases.

Authors:  Camilla Arvinius; Juan Luis Cebrián Parra; Laura Serrano Mateo; Roberto García Maroto; Alberto Francés Borrego; Luis López-Durán Stern
Journal:  Int Orthop       Date:  2013-10-15       Impact factor: 3.075

Review 5.  Surgical treatment of metastatic disease of the femur.

Authors:  K C Swanson; D J Pritchard; F H Sim
Journal:  J Am Acad Orthop Surg       Date:  2000 Jan-Feb       Impact factor: 3.020

6.  The Long Gamma Nail for stabilisation of existing and impending pathological fractures of the femur: an analysis of 48 cases.

Authors:  Kirti Moholkar; Ram Mohan; Peter Grigoris
Journal:  Acta Orthop Belg       Date:  2004-10       Impact factor: 0.500

7.  Surgical treatment of metastatic fractures of the femur: a retrospective analysis of 142 patients.

Authors:  Kambiz Sarahrudi; Manfred Greitbauer; Patrick Platzer; Jan-Till Hausmann; Thomas Heinz; Vilmos Vécsei
Journal:  J Trauma       Date:  2009-04

8.  Prophylactic stabilization for bone metastases, myeloma, or lymphoma: do we need to protect the entire bone?

Authors:  Hasham M Alvi; Timothy A Damron
Journal:  Clin Orthop Relat Res       Date:  2012-10-27       Impact factor: 4.176

Review 9.  Surgical management of metastatic bone disease.

Authors:  Jacob Bickels; Shlomo Dadia; Zvi Lidar
Journal:  J Bone Joint Surg Am       Date:  2009-06       Impact factor: 5.284

10.  A long femoral stem is not always required in hip arthroplasty for patients with proximal femur metastases.

Authors:  Zhiqing Xing; Bryan S Moon; Robert L Satcher; Patrick P Lin; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2013-01-30       Impact factor: 4.176

View more
  11 in total

1.  Outcomes of Intercalary Prosthetic Reconstruction for Pathological Diaphyseal Femoral Fractures Secondary to Metastatic Tumors.

Authors:  Hong-Chao Huang; Yong-Cheng Hu; Deng-Xing Lun; Jun Miao; Feng Wang; Xiong-Gang Yang; Xin-Long Ma
Journal:  Orthop Surg       Date:  2017-06-09       Impact factor: 2.071

2.  Association of the Anterolateral Thigh Osteomyocutaneous Flap With Femur Structural Integrity and Assessment of Prophylactic Fixation.

Authors:  Mitchell L Worley; Travis M Patterson; Evan M Graboyes; Yongren Wu; Robert M Brody; Joshua Hornig; Zeke Walton
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-09-01       Impact factor: 6.223

3.  Intramedullary Nailing Combined with Bone Grafting for Benign Lesions of the Proximal Femur.

Authors:  Yan Zhang; Jia-Zhen Li; Xin-Chang Lu; Yi Zhang; Huai-Shuan Zhang; Hai-Long Shi; Zheng Lei; Guang Feng; Wei-Ping Fu
Journal:  Orthop Surg       Date:  2017-03-16       Impact factor: 2.071

4.  What Factors Are Associated With Local Metastatic Lesion Progression After Intramedullary Nail Stabilization?

Authors:  Punthitra Arpornsuksant; Carol D Morris; Jonathan A Forsberg; Adam S Levin
Journal:  Clin Orthop Relat Res       Date:  2021-12-28       Impact factor: 4.176

5.  CORR Insights®: What Factors Are Associated With Local Metastatic Lesion Progression after Intramedullary Nail Stabilization?

Authors:  Robert L Satcher
Journal:  Clin Orthop Relat Res       Date:  2022-03-17       Impact factor: 4.176

6.  The burden of metastatic disease of the femur on the Medicare system.

Authors:  Kirollos Gendi; David Hennessy; John Heiner
Journal:  Springerplus       Date:  2016-11-04

Review 7.  The current status of prophylactic femoral intramedullary nailing for metastatic cancer.

Authors:  N M Ormsby; W Y Leong; W Wong; H E Hughes; V Swaminathan
Journal:  Ecancermedicalscience       Date:  2016-12-01

8.  The role of postoperative radiation and coordination of care in patients with metastatic bone disease of the appendicular skeleton.

Authors:  Andrew R Summers; Travis Philipp; Jacob D Mikula; Kenneth R Gundle
Journal:  Orthop Rev (Pavia)       Date:  2018-02-16

9.  Short-term outcomes of reconstruction subsequent to intercalary resection of femoral diaphyseal metastatic tumor with pathological fracture: Comparison between segmental allograft and intercalary prosthesis.

Authors:  Deng-Xing Lun; Yong-Cheng Hu; Xiong-Gang Yang; Feng Wang; Zhao-Wan Xu
Journal:  Oncol Lett       Date:  2018-01-16       Impact factor: 2.967

10.  Ambulation Recovery After Surgery for Metastases to the Femur.

Authors:  Yongsung Kim; Chandra Kumar Krishnan; Han-Soo Kim; Hwan Seong Cho; Ilkyu Han
Journal:  Oncologist       Date:  2019-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.